Abstract: Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable tablet dosage forms. Also provided is packaging that discourages the use of rapidly bioavailable acute pain medications for off-label chronic pain treatment, and that allows such dosage forms to be manufactured and stored for prolonged periods of time.

Abstract: Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable dosage forms.

Abstract: Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.

Abstract: The present invention relates to excipients for the production of rapidly bioavailable solid oral dosage forms of diclofenac. In particular, the invention relates to the use of excipients that promote the bioavailability of such formulations, including alkaline buffering agents, gas forming excipients, hygroscopic excipients, water soluble diluents, wetting agents, and particular pharmaceutically acceptable salts.

Abstract: New pharmaceutical compositions for oral use containing diclofenac preferably together with alkali metal bicarbonates in amounts of from about 20 to about 80 by weight with respect to diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other, side effects; in particular, these formulations permit to obtain in human patients higher Cmax of the active principle and shorter Tmax together with a lower coefficient of variation.

Abstract: New pharmaceutical compositions for oral use containing Diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to Diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other side effects; in particular, these formulations permit to obtain in human patients higher Cmax of the active principle and shorter Tmax together with a lower coefficient of variation.

Abstract: New pharmaceutical compositions for oral use containing Diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to Diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other side effects; in particular, these formulations permit to obtain in human patients higher Cmax of the active principle and shorter Tmax together with a lower coefficient of variation.

Abstract: New pharmaceutical compositions for oral use containing diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other, side effects; in particular, these formulations permit to obtain in human patients higher Cmax of the active principle and shorter Tmax together with a lower coefficient of variation.

Abstract: New pharmaceutical compositions for oral use containing Diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to Diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other side effects; in particular, these formulations permit to obtain in human patients higher Cmax of the active principle and shorter Tmax together with a lower coefficient of variation.

Abstract: A process is described for the preparation of granulates that contain liposoluble and hydrophobic substances, preferably steroidal substances, and that exhibit rapid and excellent water-dispersibility.

Abstract: The principal activity of the amides of ethanol-.beta.-aminophosphoric acid with active moieties having anti-inflammatory and analgesic activity (FANS) remains substantially unchanged but they have considerably lower toxicity particularly in terms of damage to the stomach.The method for their preparation is also described.

Abstract: Chewing gum tablets and their methods of preparation are disclosed. The gum tablets contain a mixture of chewing gum base and sugary microgranules with an additive agent and an active ingredient adsorbed onto their surface. A lacquer coating on the tablet contains cellulose and polyethlene glycols. The sugary microgranules are delayed release coated particles. The chewing gums act as vehicles for active ingredients. These active ingredients may be used alone or in combination in normal physical form in the form of coated microspheres.

Abstract: The L-arginine salts of the mercaptoethansulphonic acid are active in the therapy of the bladder carcinoma and in the therapy and prevention of the cistinic kidney calculi.The saline derivatives with basic aminoacids and their alkyl esters are moreover devoid of side effects.The latter derivatives are prepared by reacting, in aqueous or aqueous-alcoholic medium, equimolar amounts of mercaptoethansulphonic acid, just prepared from an organic or inorganic salt thereof, and of the desired aminoacid.

Abstract: For the preparation of compounds such as ranitidine, niperotidine and cimetidine a urea of the formula:R.sub.1 --NH--C--NH--(CH.sub.2).sub.n --SD--S--(CH.sub.2).sub.n --NH--C--NH--R.sub.1 (I)which is synthesized by reaction with a compound of formula ##STR1##[H.sub.2 N--(CH.sub.2).sub.n --S--] (IX)is converted in a first stage into the corresponding bis-carbodiimideR.sub.1 --N.dbd.C.dbd.N--(CH.sub.2).sub.n --S--S--(CH.sub.2).sub.n --N.dbd.C.dbd.N--R.sub.1 (II)by reaction with triphenylphospine and bromine in the presence of a strong base and in a second stage the diimide thus obtained is reacted with nitromethane or a saline derivative of the cyanamide.The product thus obtained is reduced at the disulfide bridge obtaining a compound of formula: ##STR2## which is reacted with: ##STR3## to obtain ranitidine and niperotidine or cimetidine respectively depending on whether the first or the second of the described reactants is used.

Abstract: To synthesize molecules with antiulcer action, specifically ranitidine, niperotidine and cimetidine, having the formula: ##STR1## wherein R.sub.1 is hydrogen or together with R.sub.2 represents the rest of a cycloaliphatic or heterocyclic optionally substituted ring with 5 or 6 carbon atoms, R.sub.2 represents H, alkyl, alkyl substituted with a simple or substituted aromatic ring or with a single or substituted heterocyclic ring, Ar represents a simple or substituted phenyl group, a simple or substituted heterocyclic aromatic group, N=1, 2, 3, 4, 5 or 6 and X represents CH--NO.sub.2, S, N--C.tbd.N, the compound (II) is prepared through the following process sequence: ##STR2## wherein Z=H, NO.sub.2, halogen and R.sub.3 =--(CH.sub.2).sub.n Ar, --(CH.sub.2).sub.n --SH, --(CH.sub.2).sub.n --S--S--(CH.sub.2).sub.n, --(CH.sub.2).sub.n --S--CH.sub.2 Ar Y being halogen.

Abstract: Derivatives of mercapthansulphonic acid are active in the therapy of the bladder carcinoma and in the therapy and prevention of the cistinic kidney calculi. The saline derivatives with basic aminoacids and their alkyl esters are moreover devoid of side effects. The saline derivatives are prepared by reacting, in aqueous or aqueous-alcoholic medium, equimolar amounts of mercaptoethansulphonic acid, just prepared from an organic or inorganic salt thereof, and of the desired aminoacid.

Abstract: For the preparation of saline derivatives of mercaptoethansulfonic acid belonging to the class of the salts of alkali metals and of the salts with basic aminoacids, the sodium salt of the acid is obtained with a process comprising the reaction between sodium bromoethansulfonate with thiobenzoic acid and sodium bicarbonate and subsequent reaction of the resulting sodium benzoylethansulfonate with ammonia in water solution.

Abstract: Ursodeoxycholic acid amides of the formula: ##STR1## wherein R is --CH.sub.2 --SO.sub.3 H or --COOH and R' is --H and --(CH.sub.2).sub.2 --CONH, --CH.sub.2 --CONH.sub.2, --(CH.sub.2).sub.2 --SCH.sub.3 or --CH.sub.2 --S--CH.sub.2 --CH.sub.2 --COOH, and their salts with inorganic and organic pharmaceutically active bases, are useful in the treatment of altered biligenetic functions and lithiasis or dyskinesia of the biliary ducts.

Abstract: Thioesters of ursodeoxycholic acid of the formula: ##STR1## wherein R represents --H, --CH.sub.3 or --COOH, and R.sub.1 represents ##STR2## are useful in the treatment of altered biligenetic functions, lithiasis or dyskinesia of the biliary ducts. The esters are prepared by reacting the mixed anhydride of ursodeoxycholic acid with an alkyl or phenyl chloroformate with the appropriate mercaptan.

Abstract: Amide derivatives of L-carnitine of formula ##STR1## wherein: R is H or a straight or branched alkanoyl group having 2-6 carbon atoms;X.sup.- is the anion of a pharmacologically acceptable acid;Y.sup.+m is the cation of an alkaline or alkaline-earth metal;n is an integer from 1 to 6;n' is either 0 or 1; andm is either 1 or 2,are more active than L-carnitine in restoring to normal in the myocardium the metabolism of fatty acids imbalanced by the administration of erucic acid. Pharmaceutical compositions containing such derivatives are effective for therapeutical treatment of hyperlipidemias, atherosclerosis and cardiovascular and metabolic disturbances related thereto.